An artificial intelligence-powered test as a digital cognitive biomarker for monitoring individuals with moderate cognitive impairment (MCI) and Alzheimer’s Disease has been validated in a recently published peer-reviewed article.

The Integrated Cognitive Assessment (ICA) is a dementia early detection test created by Cognetivity Neurosciences, a digital health company based in the United Kingdom.

A new study, published in Frontiers in Psychiatry, investigates the use of AI for these particular illnesses.

• Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
• New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
• Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
• New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
• Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean

The technology employs artificial intelligence and machine learning methods to help in the detection of early indications of impairment by assessing the functioning of vast regions of the brain in order to aid in the diagnosis of dementia. It has received regulatory clearance for clinical usage in the United Kingdom and Europe, with clinical approval in North America expected in the near future.

The study confirms the ICA’s sensitivity to early dementia symptoms and confirms that it is culture-static and bias-free, allowing for fast, global implementation, including risk-based screening in primary care.

The study discovered that the ICA performs consistently across various foreign populations. What’s crucial here is that the findings may be generalised across them without the requirement for additional settings to gather population-specific normative data.

• Myocarditis or heart attack? now you can distinguish it with “a drop of blood” – experts
• A doctor asks a patient with cognitive impairment to write a sentence and this is what he writes
• Doctors reveal how dangerous the Delta variant of COVID is – the main culprit behind India’s second wave
• State of DevOps 2019: Open source users are making faster progress
• Coronavirus Patients: A simple test that reveals who is most at risk

Most conventional cognitive tests have the drawback of requiring the gathering of language and culture-specific data in new global locations before being scaled up.

The ICA’s appropriateness was determined via a survey of more than 200 research participants from various cultures. There were no disparities in language, culture, or education when the data was compared to other techniques. The AI was able to make these assessments remotely.

The ICA is intended to identify those who require therapy as well as those who are most likely to benefit from a certain kind of pharmacological intervention in the near future.

• Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
• New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
• Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
• New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
• Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean

“The diagnostic accuracy of the ICA and its novel use of explainable AI, combined with the power to generalize across other languages and cultures, make it uniquely suitable for cognitive screening across large and diverse populations,” says lead researcher geriatric psychiatrist Professor Dag Aarsland.

Image Credit: Getty